[Not Available]. / Nivolumab dans le traitement des CBNPC.
Bull Cancer
; 103(6 Suppl 1): S12-5, 2016 Jun.
Article
en Fr
| MEDLINE
| ID: mdl-27494968
ABSTRACT
TREATMENT OF NSCLC WITH NIVOLUMAB Chemotherapy with docetaxel has remained a cornerstone of second-line treatment for more than 15 years, but it is associated with an unfavorable safety profile. Recently, the results of 2 randomized phase III trials assessing nivolumab in lung cancer, Check-Mate-017 and Check- Mate-057, have deeply changed our current clinical practice and open the debate for further improvements in the clinical care of lung cancer. This paper explores the recent findings about nivolumab in the second-line setting and discusses future directions for nivolumab and other immune Oncology drugs.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Neoplasias Pulmonares
/
Anticuerpos Monoclonales
/
Antineoplásicos
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
Fr
Revista:
Bull Cancer
Año:
2016
Tipo del documento:
Article